Research output per year
Research output per year
Personal profile
Research Interests
Anti-cancer therapeutics
Neuro oncology
Gynaecological cancers
Genitourinary cancers
Rare cancers - cancer of unknown primary, endocrine cancers and others
Supportive care
Neuro oncology
Gynaecological cancers
Genitourinary cancers
Rare cancers - cancer of unknown primary, endocrine cancers and others
Supportive care
Research Expertise
Cancer
Cancer Pharmacology
Education/Academic qualification
PhD, Flinders University
External positions
Clinical lead, Statewide Cancer Clinical Network, Commission on Excellence and Innovation in Health (CEIH)
2019 → …
SALHN, Southern Adelaide Local Health Network
Fingerprint
Dive into the research topics where Ganessan Kichenadasse is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2)
Lickliter, J. D., Voskoboynik, M., Mileshkin, L., Gan, H. K., Kichenadasse, G., Zhang, K., Zhang, M., Tang, Z. & Millward, M., 1 Feb 2022, In: British Journal of Cancer. 126, 2, p. 310 1 p., 310.Research output: Contribution to journal › Comment/debate
Open AccessFile -
C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
Abuhelwa, A. Y., Bellmunt, J., Kichenadasse, G., McKinnon, R. A., Rowland, A., Sorich, M. J. & Hopkins, A. M., 1 Aug 2022, In: Frontiers in Oncology. 12, 7 p., 918993.Research output: Contribution to journal › Article › peer-review
Open AccessFile2 Downloads (Pure) -
Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials
Hopkins, A. M., Badaoui, S., Kichenadasse, G., Karapetis, C. S., McKinnon, R. A., Rowland, A. & Sorich, M. J., Jun 2022, In: Journal of Thoracic Oncology. 17, 6, p. 758-767 10 p.Research output: Contribution to journal › Article › peer-review
5 Citations (Scopus) -
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150
Hopkins, A. M., Kichenadasse, G., McKinnon, R. A., Abuhelwa, A. Y., Logan, J. M., Badaoui, S., Karapetis, C. S., Rowland, A. & Sorich, M. J., 1 Jan 2022, In: British Journal of Cancer. 126, 1, p. 42-47 6 p.Research output: Contribution to journal › Article › peer-review
14 Citations (Scopus) -
Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy
Abuhelwa, A. Y., Bellmunt, J., Kichenadasse, G., McKinnon, R. A., Rowland, A., Sorich, M. J. & Hopkins, A. M., Apr 2022, In: Clinical Genitourinary Cancer. 20, 2, p. 132-138 7 p.Research output: Contribution to journal › Article › peer-review
1 Citation (Scopus)
Activities
- 1 Oral presentation
-
Utility of a self-management approach in lifestyle interventions for cancer survivors - preliminary findings from the NAPA trial
Sharon Lawn (Speaker), Stephanie Zrim (Speaker), Stephanie Leggett (Speaker), Michelle Miller (Speaker), L Jones (Speaker), Jim Dollman (Speaker), Sue Booth (Speaker), Richard Woodman (Speaker), Chris Karapetis (Speaker), Ganessan Kichenadasse (Speaker), Shawgi Sukumaran (Speaker) & Bogda Koczwara (Speaker)
6 Feb 2013Activity: Talk or presentation types › Oral presentation